Aileron Therapeutics has entered into a clinical collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE, in MDM2-amplified cancers. Overexpression of MDM2 in cancer is typically a driver of tumor proliferation. Aileron expects to start enrolling patients with solid tumors in the Phase IB trial in 1Q19. Pfizer will provide drug supply in support of the trial.  ALRN-6924 is a first-in-class, stabilized cell-permeating peptide...